







CellDetect[®] Bladder

Urine-Based Cytochemical Stain Providing Color Differentiation Between Normal and Malignant Cells Alongside Morphology

-  **Easy** Fully reproducible
-  **Quick** 20-minute staining protocol
-  **Reliable** Validated increased accuracy across all tumor grades
-  **Cost-effective** Standard laboratory workflow


The non-invasive solution for detection and surveillance of bladder cancer cytopathologists have been waiting for

CellDetect® Bladder


Clinical Benefits

- Increased detection of recurrent and de-novo cancer
- Reduced inconclusive cytology readings
- Early diagnosis of high-grade and low-grade tumors
- Applicable for both MIBC and NMIBC
- Increased detection of flat lesions


Interpretation Made Easy



NORMAL CELLS



LG TUMOR



HG TUMOR

Accumulated Clinical Evidence

Test	Sensitivity %	Specificity %
CellDetect®	92	80
Cytology	46	93

Germany (n=66, 2018)

Test	Sensitivity %	Specificity %
CellDetect®	100	81
Cytology	50	98


Johns Hopkins Medicine, USA (n=62, 2018)

Test	Sensitivity %	Specificity %
CellDetect®	100	85
Cytology	43	96

Greater Boston Urology, USA (n=63, 2018)

Test	Sensitivity %	Specificity %
CellDetect®	84	83
Cytology	50	89

Multicenter, Israel (n=217, 2015)



OVERALL PERFORMANCE

Sensitivity	92%
Specificity	83%
NPV	99%



Micromedic Technologies (TASE: MCTC) is engaged in the development and commercialization of unique solutions addressing real needs prevailing in the field of cancer diagnostics and early cancer detection.

CellDetect® is a trademark of ZetiQ, a fully-owned subsidiary of Micromedic.



EC REP MedNet GmbH, Borkstrasse 10,
48163, Münster, Germany